Clinical Usefulness of ^99mTc-HYNIC-TOC and ¹³¹I-MIBG Scintigraphy in the Evaluation of Adrenal Tumors

1. Lirov R, Else T, Lerario AM, Hammer GD. Adrenal Tumors. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: principles & practice of oncology. 10h ed. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins; 2015.Search in Google Scholar

2. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors. Eur J Endocrin. 2016;175(2):G1-34.10.1530/EJE-16-046727390021Search in Google Scholar

3. Kumari NS, Sireesha A, Jayashree K, Kumar OS. Spectrum of histomorphological patterns of adrenal tumors: A one year study at Gandhi Hospital, Hyderabad - A tertiary referral centre. IAIM, 2016; 3(7): 77-86.Search in Google Scholar

4. Tang YZ, Bharwani N, Micco M, Akker S, Rockall AG, Sahdev A. The prevalence of incidentally detected adrenal enlargement on CT. Clin Radiol. 2014 Jan 31;69(1):e37-42.10.1016/j.crad.2013.08.01724161458Search in Google Scholar

5. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. AJR Am J Roentgenol. 2008;190(5):1163-8.10.2214/AJR.07.279918430826Search in Google Scholar

6. Reginelli A, Di Grezia G, Izzo A, et al, 2014 Imaging of adrenal incidentaloma: our experience. Int J Surg 12: Suppl 1: 126-31.10.1016/j.ijsu.2014.05.02924862667Search in Google Scholar

7. Terzolo M, Stigliano A, Chiodini I, Loli P, Furlani L, Arnaldi G, et al. AME position statement on adrenal incidentaloma. Eur J Endocrin. 2011;164(6):851-70.10.1530/EJE-10-114721471169Search in Google Scholar

8. Patel RD, Vanikar AV, Suthar KS, Kanodia KV. Primary Adrenal Tumors-Five Years Single Centre Experience. J Pathol. 2012;2(04):107.10.4236/ojpathology.2012.24020Search in Google Scholar

9. Morelli V, Palmieri S, Salcuni AS, et al. Bilateral and unilateral adrenal incidentalomas: biochemical and clinical characteristics. Eur J Endocrinol 2013;168:235–41.10.1530/EJE-12-077723169694Search in Google Scholar

10. Khanna S, Priya R, Bhartiya SK, Basu S, Shukla VK. Adrenal tumors: An experience of 10 years in a single surgical unit. Indian J Cancer. 2015;52(3):475.10.4103/0019-509X.17674926905175Search in Google Scholar

11. Naidu V, Singh B. Adrenal lesions encountered in current medical practice − a review of their radiological imaging. S Afr J Rad. 2013;17:128–38. DOI:10.7196/SAJR.914.10.7196/sajr.914Open DOISearch in Google Scholar

12. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E & Kharlip J. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine Practice 2009;15:1–20.10.4158/EP.15.S1.119632967Open DOISearch in Google Scholar

13. Sundin A. Imaging of adrenal masses with emphasis on adrenocortical tumors. Theranostics. 2012;2:516-22.10.7150/thno.3613336455722737189Search in Google Scholar

14. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007 Sep;14(3):587-99.1791409010.1677/ERC-07-004517914090Search in Google Scholar

15. Maurea S, Mainenti PP, Ponsiglione A, Salvatore M. Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques. J Adv Radiol Med Image. 2016;1(1):103.Search in Google Scholar

16. Heinz-Peer G, Honigschnabl S, Schneider B, Niederle B, Kaserer K, Lechner G. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol. 1999;173:15-22.10.2214/ajr.173.1.1039709210397092Search in Google Scholar

17. Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194(6):1450-6010.2214/AJR.10.454720489083Search in Google Scholar

18. Boland GW, Lee M, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201-4.10.2214/ajr.171.1.96487899648789Search in Google Scholar

19. Rubello D, Bui C, Casara D, Gross MD, Fig LM, Shapiro B. Functional scintigraphy of the adrenal gland. Eur J Endocrin. 2002;147(1):13-28.10.1530/eje.0.147001312088915Search in Google Scholar

20. Avram AM, Fig LM, Gross MD. Adrenal gland scintigraphy. Semin Nucl Med. 2006 Jul;36(3):212-27.10.1053/j.semnuclmed.2006.03.00416762612Open DOISearch in Google Scholar

21. Blanchet EM, Martucci V, Pacak K. Pheochromocytoma and paraganglioma: current functional and future molecular imaging. Front Oncol. 2012;1:58.10.3389/fonc.2011.00058335614022655253Search in Google Scholar

22. McDermott S, McCarthy CJ, Blake MA. Images of pheochromocytoma in adrenal glands. Gland surg. 2015;4(4):350.Search in Google Scholar

23. Maurea S, Mainenti PP, Ponsiglione A, Salvatore M. Advanced Adrenal Imaging: Comparison between Radionuclide and MR Techniques. J Adv Radiol Med Image. 2016;1(1):103.Search in Google Scholar

24. Wiseman GA, Pacak K, O’Dorisio MS, Neumann DR, Waxman AD, Mankoff DA, et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med. 2009;50(9):1448-54.10.2967/jnumed.108.058701472280719690028Search in Google Scholar

25. van Berkel A, Rao JU, Lenders JW, Pellegata NS, Kusters B, Piscaer I, Hermus AR, et al. Semiquantitative 123IMetaiodobenzylguanidine scintigraphy to distinguish pheochromocytoma and paraganglioma from physiologic adrenal uptake and its correlation with genotype-dependent expression of catecholamine transporters. J Nucl Med. 2015;56(6):839-46.10.2967/jnumed.115.15481525883126Search in Google Scholar

26. Ziegler CG, Brown JW, Schally AV, Erler A, Gebauer L, Treszl A, et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc Natl Acad Sci USA. 2009;106(37):15879-84. doi: 10.1073/pnas.0907843106. Epub 2009 Aug 27.10.1073/pnas.0907843106.Epub2009Aug27Open DOISearch in Google Scholar

27. Pisarek H, St Thepieñ T, Kubiak R, Pawlikowski M. Somatostatin receptors in human adrenal gland tumors–immunohistochemical study. Folia Histochem Cytobiol. 2008;46(3):345-51. doi: 10.2478/v10042-008-0051-2.10.2478/v10042-008-0051-219056539Open DOISearch in Google Scholar

28. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine’s view. J Pharm Pharm Sci. 2007;10(2):321s-7sSearch in Google Scholar

29. Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol. 2015;2:159–68.10.2217/ije.14.40452614126257863Search in Google Scholar

30. Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Walz MK, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012;39(12):1977–95.10.1007/s00259-012-2215-8471477222926712Search in Google Scholar

31. Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37:1441–48.10.1007/s00259-010-1473-620461371Search in Google Scholar

32. Doknić M, Pekić S, Miljić D, Stojanović M, Soldatovic I, Petakov M. Etiology of hypopituitarism in adult patients: the experience of a single center database 1 in Serbian population. Int J Endocrinol. In press 2017. Available from: https://www.hindawi.com/journals/ije/aip/6969286/.10.1155/2017/6969286549408028702053Open DOISearch in Google Scholar

33. Novakovic Paro J, Mitrovic M, Medis Stojanoska M, Bajkin I, Icin T, Tomic D, et al. Epidemiological study of adrenal mass in our clinical centre. 11th European Congress of Endocrinology, Istanbul, Turkey 2009, Endocrine abstracts, vol 20, P 38.Search in Google Scholar

34. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014;38(1):7-41. doi: 10.1016/j.currproblcancer.2014.01.001. Epub 2014 Jan 15.10.1016/j.currproblcancer.2014.01.001.Epub201415Open DOISearch in Google Scholar

35. Kapoor A, Morris T, Rebello R. Guidelines for the management of the incidentally discovered adrenal mass. Can Urol Assoc J 2011;5:241–247.10.5489/cuaj.11135314703621801680Search in Google Scholar

36. Northcutt BG, Raman SP, Long C, Oshmyansky AR, Siegelman SS, Fishman EK, et al. MDCT of adrenal masses: can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?. Am J Roentgenol. 2013;201(4):834-9.10.2214/AJR.12.975324059372Search in Google Scholar

37. Schieda N, Alrashed A, Flood TA, Samji K, Shabana W, McInnes MD. Comparison of quantitative MRI and CT washout analysis for differentiation of adrenal pheochromocytoma from adrenal adenoma. Am J Roentgenol. 2016;206(6):1141-8.10.2214/AJR.15.1531827011100Search in Google Scholar

38. Leung K, Stamm M, Raja A, Low G. Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging. Am J Roentgenol. 2013 Feb;200(2):370–37810.2214/AJR.12.912623345359Search in Google Scholar

39. Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [¹²³I] metaiodobenzylguanidine and [¹¹¹In] octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86(2):685-93.10.1210/jc.86.2.685Search in Google Scholar